PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the safety and effectiveness of baloxavir marboxil (baloxavir) and oseltamivir in pediatric influenza patients in China.
UNASSIGNED: Patients filling a prescription for baloxavir or oseltamivir within 48 h following an influenza-related outpatient visit were identified in Children\'s Hospital of Fudan University in China between March 2023 and December 2023. Outcomes were assessed after antiviral treatment and included the incidence of adverse reactions and the duration of fever and other flu symptoms.
UNASSIGNED: A total of 1430 patients infected with influenza A were collected and 865 patients (baloxavir: n = 420; oseltamivir: n = 445) finally included. The incidence of adverse reactions of nausea and vomiting was significantly different between the baloxavir group (2.38%) and the oseltamivir group (12.13%) [P < 0.001, OR = 4.2526, 95%CI (2.0549, 9.6080)]. No differences in other adverse reactions were observed between the two groups. The mean duration of fever in baloxavir group (1.43d) was significantly shorter than that in oseltamivir group (2.31d) [P < 0.001, 95%CI (0.7815, 0.9917)]. There were no differences in the mean duration of nasal congestion and runny nose, sore throat, cough, and muscle soreness between two groups.
UNASSIGNED: The incidence of nausea and vomiting is lower with baloxavir compared to oseltamivir, and the duration for complete fever reduction is shorter with baloxavir than with oseltamivir. The results indicate that baloxavir is well tolerated and effective in Chinese children.
UNASSIGNED: Patients filling a prescription for baloxavir or oseltamivir within 48 h following an influenza-related outpatient visit were identified in Children\'s Hospital of Fudan University in China between March 2023 and December 2023. Outcomes were assessed after antiviral treatment and included the incidence of adverse reactions and the duration of fever and other flu symptoms.
UNASSIGNED: A total of 1430 patients infected with influenza A were collected and 865 patients (baloxavir: n = 420; oseltamivir: n = 445) finally included. The incidence of adverse reactions of nausea and vomiting was significantly different between the baloxavir group (2.38%) and the oseltamivir group (12.13%) [P < 0.001, OR = 4.2526, 95%CI (2.0549, 9.6080)]. No differences in other adverse reactions were observed between the two groups. The mean duration of fever in baloxavir group (1.43d) was significantly shorter than that in oseltamivir group (2.31d) [P < 0.001, 95%CI (0.7815, 0.9917)]. There were no differences in the mean duration of nasal congestion and runny nose, sore throat, cough, and muscle soreness between two groups.
UNASSIGNED: The incidence of nausea and vomiting is lower with baloxavir compared to oseltamivir, and the duration for complete fever reduction is shorter with baloxavir than with oseltamivir. The results indicate that baloxavir is well tolerated and effective in Chinese children.
摘要：
■评估巴洛沙韦（baloxavir）和奥司他韦在中国儿科流感患者中的安全性和有效性。
在2023年3月至2023年12月期间，在中国复旦大学儿童医院确定了与流感相关的门诊就诊后48小时内服用巴洛沙韦或奥司他韦处方的患者。在抗病毒治疗后评估结果，包括不良反应的发生率以及发热和其他流感症状的持续时间。
■共收集了1430例感染甲型流感的患者，最终包括865例患者（巴洛沙韦：n=420；奥司他韦：n=445）。巴洛他韦组恶心呕吐不良反应发生率(2.38%)与奥司他韦组(12.13%)比较差异有统计学意义[P<0.001,OR=4.2526,95CI(2.0549,9.6080)]。两组患者在其他不良反应方面无明显差异。巴洛他韦组平均发热持续时间(1.43d)明显短于奥司他韦组(2.31d)[P<0.001,95CI(0.7815,0.9917)]。鼻塞和流涕的平均持续时间没有差异，喉咙痛,咳嗽,两组之间的肌肉酸痛。
■与奥司他韦相比，巴洛沙韦的恶心和呕吐发生率较低，巴洛沙韦完全退烧的持续时间比奥司他韦更短。结果表明，巴洛沙韦在中国儿童中具有良好的耐受性和有效性。
在2023年3月至2023年12月期间，在中国复旦大学儿童医院确定了与流感相关的门诊就诊后48小时内服用巴洛沙韦或奥司他韦处方的患者。在抗病毒治疗后评估结果，包括不良反应的发生率以及发热和其他流感症状的持续时间。
■共收集了1430例感染甲型流感的患者，最终包括865例患者（巴洛沙韦：n=420；奥司他韦：n=445）。巴洛他韦组恶心呕吐不良反应发生率(2.38%)与奥司他韦组(12.13%)比较差异有统计学意义[P<0.001,OR=4.2526,95CI(2.0549,9.6080)]。两组患者在其他不良反应方面无明显差异。巴洛他韦组平均发热持续时间(1.43d)明显短于奥司他韦组(2.31d)[P<0.001,95CI(0.7815,0.9917)]。鼻塞和流涕的平均持续时间没有差异，喉咙痛,咳嗽,两组之间的肌肉酸痛。
■与奥司他韦相比，巴洛沙韦的恶心和呕吐发生率较低，巴洛沙韦完全退烧的持续时间比奥司他韦更短。结果表明，巴洛沙韦在中国儿童中具有良好的耐受性和有效性。
